ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: 84% Of Micromet Shares Have Been Tendered

DOW JONES NEWSWIRES Amgen Inc. (AMGN) said nearly 84% of the shares of biotechnology company Micromet Inc. (MITI) have been tendered to its $1.16 billion takeover offer, meeting all the conditions for the acquisition to close. As of the offering's expiration Thursday, about 80 million Micromet shares had been tendered and not withdrawn. An added 3.15 million shares have been tendered by guaranteed delivery. A subsequent offering period is scheduled to expire at 12:00 a.m. EST, at the end of March 6. Amgen launched its bid to acquire Micromet in January with an aim to strengthen Amgen's cancer-drug research pipeline. A Delaware judge declined to block Amgen's purchase of Micromet, the Associated Press reported Thursday. A group of Micromet shareholders had argued that Micromet didn't try hard enough to get a better offer, and sought a preliminary injunction. The judge found that the shareholders didn't show a reasonable likelihood that they would successfully prove their claims, the AP reported. Amgen shares closed at $67.59 Thursday and were inactive premarket. The stock is up 32% in the past 12 months. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/19/201509:16:45MARKET SNAPSHOT: Peak Earnings Week To Follow Big Global Selloff
04/18/201511:04:02The 3 Best Stocks for Investing in Cholesterol Drugs
04/16/201516:05:00Amgen Announces Webcast Of 2015 First Quarter Financial Results
04/15/201519:52:41Correction to Corlanor Article
04/15/201518:40:08FDA Approves Amgen's Heart-Failure Drug Corlanor -- Update
04/15/201518:31:09FDA Approves Amgen's Heart-Failure Drug Corlanor
04/15/201518:25:44FDA Approves Amgen's Heart-Failure Drug Corlanor
04/15/201517:04:00FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization...
04/15/201508:59:033 Biotech Stocks That May Disappear Before 2020
04/13/201516:06:44Additional Proxy Soliciting Materials (definitive) (defa14a)
04/13/201510:42:08Radius Health: Flying Under The Radar With An Exceptional Pipeline
04/11/201515:02:0310 Largest Companies by Market Cap in Biotech
04/11/201514:02:03How Amgen Could Side-Step The Sting of Patent Expiration
04/11/201503:51:07Immunotherapy: Unleashing The Immune System To Decimate Cancer
04/09/201517:59:09Why Investors Shouldn't Worry About Explosive New Drug Pricing:...
04/08/201513:19:07Chasing - And Surviving - Today's Income Storm
04/06/201508:01:17Could Celgene Corporation Muscle Its Way Past Amgen Inc.?
04/06/201507:20:30Expanded indication for Amgen's Vectibix cleared in Europe
04/06/201505:00:00European Commission Approves Amgen's Vectibix® (panitumumab...
04/05/201509:52:02Can This Pharma Go From Good to Great?

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad